Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

BACKGROUND: Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Thoracic tumor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389252/
https://www.ncbi.nlm.nih.gov/pubmed/31125062
http://dx.doi.org/10.1093/annonc/mdz167

Ejemplares similares

Ejemplares similares